You are here: Industry Insights > Market News > North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Brexpiprazole Intermediate CAS:70500-72-0

Brexpiprazole CAS:913611-97-9

3-BROMOPHENANTHRENE

2-FLUORO-4-(TRIFLUOROMETHYL)BENZOPHENONE

3-BROMO-4-FLUOROBIPHENYL

9-TRIFLUOROACETYLANTHRACENE

North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray

biospaceDecember 25, 2017

Tag: Insys , bribe

Favorites

North Carolina sued Insys on Thursday, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys to boost profits amid the U.S. opioid epidemic.

The lawsuit announced by North Carolina Attorney General Josh Stein comes amid a federal investigation that has led to charges against several former executives accused of engaging in a scheme to bribe doctors to prescribe Subsys.

Previous:Janssen Forges Global Pact With Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy

Next:FDA approves Ortho’s HIV diagnostic test

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>